Puca, P.; Del Gaudio, A.; Iaccarino, J.; Blasi, V.; Coppola, G.; Laterza, L.; Lopetuso, L.R.; Colantuono, S.; Gasbarrini, A.; Scaldaferri, F.;
et al. Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data. Cancers 2025, 17, 735.
https://doi.org/10.3390/cancers17050735
AMA Style
Puca P, Del Gaudio A, Iaccarino J, Blasi V, Coppola G, Laterza L, Lopetuso LR, Colantuono S, Gasbarrini A, Scaldaferri F,
et al. Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data. Cancers. 2025; 17(5):735.
https://doi.org/10.3390/cancers17050735
Chicago/Turabian Style
Puca, Pierluigi, Angelo Del Gaudio, Jacopo Iaccarino, Valentina Blasi, Gaetano Coppola, Lucrezia Laterza, Loris Riccardo Lopetuso, Stefania Colantuono, Antonio Gasbarrini, Franco Scaldaferri,
and et al. 2025. "Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data" Cancers 17, no. 5: 735.
https://doi.org/10.3390/cancers17050735
APA Style
Puca, P., Del Gaudio, A., Iaccarino, J., Blasi, V., Coppola, G., Laterza, L., Lopetuso, L. R., Colantuono, S., Gasbarrini, A., Scaldaferri, F., & Papa, A.
(2025). Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data. Cancers, 17(5), 735.
https://doi.org/10.3390/cancers17050735
